home / stock / alt / alt news

ALT News and Press, Altimmune Inc.

Stock Information
Company Name: Altimmune Inc.
Stock Symbol: ALT
Market: NASDAQ
Website: altimmune.com
Menu
ALT ALT Quote ALT Short ALT News ALT Articles ALT Message Board
Get ALT Alerts

News, Short Squeeze, Breakout and More Instantly...
ALT - Altimmune: The High Cost Of Going Solo (Rating Downgrade)

2026-03-12 14:47:28 ET Overview Altimmune, Inc. ( ALT ) is a curious stock. By all metrics, it’s undervalued/underappreciated. Its GLP-1/glucagon agonist, pemvidutide, is prepping for a Phase 3 MASH program. Even conservative probability of success/peak share estimates re...
ALT - Altimmune, Inc. (ALT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

2026-03-12 13:02:23 ET Altimmune, Inc. (ALT) Barclays 28th Annual Global Healthcare Conference March 12, 2026 10:30 AM EDT... Read the full article on Seeking Alpha For further details see: Altimmune, Inc. (ALT) Presents at Barclays 28th Annual Global Healthcare Conference T...

ALT - Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away

2026-03-06 08:37:16 ET Thesis Altimmune, Inc. ( ALT ) has just reported a 4Q25 GAAP EPS of -$0.27, a figure which missed analyst expectations by about $0.03. Now, even with the earnings miss, the company did still manage to post some revenue, about of $0.03 million, which ac...

ALT - Altimmune outlines 1,800-patient Phase III MASH trial and signals cash runway into 2028 as pemvidutide advances

2026-03-05 14:16:56 ET More on Altimmune Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 Altimmune: Why Breakthrough Status Isn't A 'Buy' Signal Just Yet Altimmune to start late-stage tria...
ALT - Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript

2026-03-05 14:15:56 ET Altimmune, Inc. (ALT) Q4 2025 Earnings Call March 5, 2026 8:30 AM EST Company Participants Jerome Durso - Chairman, CEO & President Christophe Arbet-Engels - Chief Medical Officer Linda Richardson - Chief Commercial Officer Gregory ...

ALT - Altimmune to start late-stage trial for MASH candidate this year

2026-03-05 11:49:05 ET More on Altimmune Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 Altimmune: Why Breakthrough Status Isn't A 'Buy' Signal Just Yet Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen Altimmune prices ...

ALT - Altimmune (ALT) Q4 2025 Earnings Call Transcript

2026-03-05 11:43:43 ET Image source: The Motley Fool. Thursday, March 5, 2026 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading
ALT - Altimmune GAAP EPS of -$0.27 misses by $0.03, revenue of $0.03M beats by $0.03M

2026-03-05 07:06:06 ET More on Altimmune Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 Altimmune: Why Breakthrough Status Isn't A 'Buy' Signal Just Yet Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen Altimmune prices ...

ALT - Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates

Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD) expected in third quarter 2026 Cash, cash equivalents and short-term investments of ...

ALT - Expected US Company Earnings on Thursday, March 5th, 2026

Transportadora de Gas del Sur SA TGS (TGS) is expected to report $0.51 for Q4 2025 John Wiley & Sons Inc. (WLY) is expected to report $0.86 for Q3 2026 Foghorn Therapeutics Inc. (FHTX) is expected to report $-0.28 for Q4 2025 Costco Wholesale Corporation (COST) is expected to repo...
Next 10